Efficacy and safety of silodosin on lower urinary tract symptoms (LUTS) in patients with Parkinson's disease
Not Applicable
- Conditions
- Parkinson's disease
- Registration Number
- JPRN-UMIN000008138
- Lead Sponsor
- Juntendo University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who 1) is taking other alpha 1-blockers (Harnal, Flivas), or who cannot do washout taking these drugs 2) had taken anti-androgens or 5 alpha-reductase inhibitors 6 months before the informed consent 3) cannot quit concomitant medications. 4) Cannot record subjective symptoms because of dementia etc. (23>=MMSE) 5) have had surgical treatment such as TURP, thermo thrapy, HoLEP etc. 6) primary physician judged as inadequate to entry in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in IPSS total score before and after administration of silodosin
- Secondary Outcome Measures
Name Time Method QOL score, OABSS, Blood pressure, Adverse events